Companies Like 4SC (ETR:VSCA) Could Be Quite Risky
Jan 15
German (DAX) Biotech Industry Analysis
UpdatedJan 31, 2023
DataAggregated Company Financials
Companies12
- 7D-2.1%
- 3M3.4%
- 1Y9.0%
- YTD-3.7%
Over the last 7 days, the Biotech industry has dropped 2.1%, driven by Formycon declining 5.3%. Over the past 12 months, the industry was up 9.0%. As for the next few years, earnings are expected to grow by 55% per annum.
Industry Valuation and Performance
Has the German Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 31 Jan 2023 | €3.0b | €611.9m | -€53,407,435.00 | 10.7x | -55.7x | 4.9x |
| Thu, 29 Dec 2022 | €3.0b | €611.9m | -€53,407,435.00 | 11.1x | -56.2x | 4.9x |
| Sat, 26 Nov 2022 | €3.0b | €611.8m | -€48,604,435.00 | 11.1x | -62x | 4.9x |
| Mon, 24 Oct 2022 | €2.6b | €627.4m | -€129,805,157.00 | 6x | -19.7x | 4.1x |
| Wed, 21 Sep 2022 | €2.6b | €627.4m | -€129,805,157.00 | 5.4x | -20x | 4.1x |
| Fri, 19 Aug 2022 | €2.8b | €605.7m | -€150,021,513.00 | 6.3x | -18.6x | 4.6x |
| Sun, 17 Jul 2022 | €3.4b | €772.0m | -€724,268,362.00 | n/a | -4.6x | 4.4x |
| Tue, 14 Jun 2022 | €3.2b | €768.8m | -€724,082,241.00 | n/a | -4.5x | 4.2x |
| Thu, 12 May 2022 | €3.2b | €769.9m | -€723,863,944.00 | n/a | -4.4x | 4.1x |
| Sat, 09 Apr 2022 | €3.8b | €808.9m | -€704,269,813.00 | n/a | -5.4x | 4.7x |
| Mon, 07 Mar 2022 | €3.4b | €789.6m | -€311,283,353.00 | n/a | -11x | 4.3x |
| Wed, 02 Feb 2022 | €3.7b | €789.6m | -€311,283,353.00 | n/a | -12x | 4.7x |
| Fri, 31 Dec 2021 | €4.1b | €789.6m | -€311,690,565.00 | n/a | -13x | 5.1x |
| Sun, 28 Nov 2021 | €4.1b | €789.6m | -€311,690,565.00 | n/a | -13.1x | 5.2x |
| Tue, 26 Oct 2021 | €4.5b | €771.2m | -€257,628,521.00 | n/a | -17.5x | 5.8x |
| Thu, 23 Sep 2021 | €4.3b | €764.0m | -€156,817,446.00 | 1.3x | -27.5x | 5.6x |
| Sat, 21 Aug 2021 | €4.2b | €769.4m | -€175,243,228.00 | 1.4x | -24x | 5.5x |
| Sat, 05 Jun 2021 | €5.0b | €742.3m | -€215,931,793.00 | 1.3x | -23x | 6.7x |
| Tue, 09 Mar 2021 | €5.7b | €929.7m | -€78,349,962.23 | 27.9x | -72.9x | 6.1x |
| Mon, 30 Nov 2020 | €5.4b | €857.0m | -€138,041,722.02 | 68x | -39.1x | 6.3x |
| Thu, 03 Sep 2020 | €6.2b | €856.0m | -€124,654,217.95 | 32.8x | -49.7x | 7.2x |
| Sun, 07 Jun 2020 | €6.1b | €859.6m | -€127,445,277.32 | 25x | -47.5x | 7x |
| Sat, 29 Feb 2020 | €5.1b | €602.0m | -€403,838,466.74 | n/a | -12.7x | 8.5x |
Price to Earnings Ratio
-14.9x
Current Industry PE
- Investors are pessimistic on the German Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.7x is higher than the industry's current PS ratio of 4.9x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that companies overall are more efficiently conducting business since losses are shrinking while sales have been flat.
Industry Trends
Which industries have driven the changes within the German Healthcare industry?
| DE Market | 0.26% | |
| Healthcare | 0.31% | |
| Biotech | -2.10% | |
| Biotech | -2.10% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| MOR MorphoSys | €18.00 | 2.5% +€15.0m | -36.3% | PS2.5x | |
| T5O bioXXmed | €3.32 | 130.6% +€9.7m | -21.7% | PS383.5x | |
| PA8 Paion | €0.71 | 19.7% +€8.3m | -47.4% | PS1.8x | |
| HPHA Heidelberg Pharma | €5.12 | 2.0% +€4.7m | 18.9% | PS13.8x | |
| 2INV 2invest | €8.88 | 3.5% +€1.7m | -31.7% | PS17.4x |